Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 3/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9347958 | 0.86 | SLC18A3 (0.46) | SLC18A3LIPETLR8TLR7TLR9 | |
| Hydrochloric Acid SCHEMBL9343733 | 0.85 | SLC18A3 (0.44) | SLC18A3LIPETLR8TLR7TLR9 | |
| SCHEMBL15317715 | 0.83 | KMT2A (0.50) | SLC18A3LIPETLR8TLR7TLR9 | |
| SCHEMBL16994792 | 0.83 | SLC18A3 (0.51) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL13179269 | 0.81 | DRD2 (0.50) | SLC18A3LIPETP53DRD2SIGMAR1 | |
| SCHEMBL17306126 | 0.80 | SLC18A3 (0.49) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL4519074 | 0.80 | SLC18A3 (0.52) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL4404011 | 0.80 | DRD2 (0.50) | SLC18A3TP53DRD2SIGMAR1DRD4 | |
| SCHEMBL17630951 | 0.80 | SLC18A3 (0.48) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL29964208 | 0.80 | SLC18A3 (0.57) | SLC18A3TLR8TLR7TLR9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | SLC18A3 3774/4885LIPE 2549/4885TLR8 1899/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | SLC18A3 3774/4885LIPE 2549/4885TLR8 1899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.